Mesothelioma Clinical Trials
A Pilot Phase 2 Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Advanced Malignant Mesothelioma
Endpoint of Research:
To determine the response rate of zoledronic acid (brand name Zometa, Reclast in mesothelioma clinical trials – used to prevent skeletal fractures) using a various criteria including the European Organization for Research and Treatment of Cancer modified RECIST (Response Evaluation Criteria In Solid Tumors) criteria.
Study Location:
Birmingham, Alabama
Contact: Mary L. Jerome, RN
205-934-5092
Mary.Jerome@ccc.uab.edu
Alma F. DelGrosso, RN, BSN, OCN
205-934-0337
Alma.DelGrosso@ccc.uab.edu
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients with Advanced Solid Tumors and in Chemotherapy-naïve Patients with Malignant Pleural Mesothelioma
Endpoint of Research:
Phase I of mesothelioma clinical trials will investigate the maximum tolerated dose of CBP501 (experimental drug that kills cancer cells by preventing them from completing the cell cycle) combined with full-dose cisplatin and pemetrexed in patients with solid malignancy that has spread or is inoperable and for which standard care is no longer effective. The phase II part of mesothelioma clinical trials will evaluate full-dose cisplatin and pemetrexed combined with the maximum tolerated dose of CBP501 in previously untreated malignant pleural mesothelioma patients, or those whose tumor is inoperable.
Study Locations:
- Scottsdale, Arizona
Contact: Mayo Clinic
Helen Ross, MD
480-301-4976
- Tucson, Arizona
Contact: Arizona Cancer Center
Lorraine Rudzitis
520-626-9001
- Duarte, California
Contact: City of Hope
Marianna Koczywas, MD
626-301-8393
- Chicago, Illinois
Contact: University of Chicago
Hedy Kindler, MD
773-702-1668
- Detroit, Michigan
Contact: Karmanos Cancer Institute/Wayne State University
Maureen Kelly
313-578-4405
- Las Vegas, Nevada
Contact: Nevada Cancer Institute
John Ruckdeschel, MD
702-822-5433
- Albuquerque, New Mexico
Contact: University of New Mexico Cancer Center
Claire Verschraegen
505-272-6760
- New York City, New York
Contact: Memorial-Sloan Kettering Cancer Center
Lee M Krug, MD
212-639-8420
- Cleveland, Ohio
Contact: Cleveland Clinic
Cristina Rodriguez, MD
216-444-9452
- Hershey, Pennsylvania
Contact: Penn State Milton S. Hershey Medical Center
Chandra Belani
717-531-5471
- Salt Lake City, Utah
Contact: Huntsman Cancer Institute
Sunil Sharma, MD
801-587-4779
Phase II of Mesothelioma Clinical Trials – Study of Milataxel (TL139) Administered Orally in Patients with Malignant Mesothelioma
Endpoint of Research:
Milataxel is a new taxane (drug classification that stops the function of microtubules, which are necessary for cell division) that may be effective in the treatment of malignant Mesothelioma patients whose disease returned or progressed after chemotherapy. This trial will evaluate response rate of this patient population to the drug.
Study Locations:
- Chicago, Illinois
Contact: University of Chicago
Sarah Mauro
773-834-3263
smauro@medicine.bsd.uchicago.edu
- New York City, New York
Contact: New York University Cancer Center
Harvey Pass, M.D.
212-731-5414
harvey.pass@med.nyu.edu
Phase II – Mesothelioma Clinical Trials Toxicity Study Using Chemotherapy +/- Pleurectomy/Decortication Followed By Intensity Modulated Radiation Therapy to the Pleura in Patients with Locally Advanced Malignant Pleural Mesothelioma.
Endpoint of Research:
A new radiation technique using Intensity Modulated Radiation Therapy (IMRT) appears to reduce many of the side effects of standard radiation therapy. It specifically targets the cancer in the lining of the lung, and reduces the risk of damaging the lung itself. This study will evaluate the safety and toxicity of standard chemotherapy with/without pleurectomy/decortication followed by IMRT to the pleura in patients with malignant pleural mesothelioma.
Study Locations:
- Basking Ridge, New Jersey; Commack, Rockville Centre, New York City, and Sleepy Hollow, New York
Contact: Memorial Sloan-Kettering Cancer Center
Lee Krug, MD
212-639-8420
A Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide In Patients With Unresectable Or Metastatic Soft Tissue Sarcoma or Malignant Mesothelioma
Endpoint of Research:
This is Phase I of a three year study to determine safety and toxicity for the combination of Temozolomide (brand Name Temodar – damages DNA of cancer cells) and Azacitidine (brand name Vidaza – used to treat myelodysplastic syndrome) in the treatment of Advanced Soft Tissue Sarcoma or Malignant Mesothelioma.
Study Location:
- New York City, New York
Contact:Columbia University Medical Center
Danielle Banks
212-305-3846
db2707@columbia.edu
